Key statistics dashboard for CRISPR Therapeutics AG (CRSP). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
CRISPR Therapeutics AG (CRSP) is a biotechnology firm dedicated to pioneering gene-based medicines for severe diseases. The company achieves this through its exclusive Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) technology, which enables precise and targeted alterations to an organism's genetic code.
Stock Data
| Price | $52.21 |
| Market Cap | $5.0B |
| Enterprise Value | $5.53B |
| Beta | 1.79 |
| Exchange | NASDAQ |
| Country | CH |
Valuation Multiples
| P/E Ratio | -10.97 |
| Price / Book | 2.89 |
| P/S | 376.01 |
| EV/EBITDA | -12.18 |
| EV/Sales | 412.78 |
| EV/FCF | -11.50 |
| P/FCF | -10.47 |
| Earnings Yield | -8.95% |
| FCF Yield | -9.55% |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | -1534.39% |
| EBIT Margin | -3529.79% |
| EBITDA Margin | -3390.05% |
| Operating Margin | -3971.53% |
| Net Margin | -3368.72% |
| Return on Equity | -24.39% |
| Return on Assets | -17.02% |
| Return on Invested Capital | -20.97% |
| Return on Capital Employed | -21.12% |
Financial Health
| Current Ratio | 17.85 |
| Quick Ratio | 17.85 |
| Cash Ratio | 2.19 |
| Debt / Equity | 0.45 |
| Debt / Assets | 29.57% |
| Net Debt / EBITDA | -1.08 |
| Interest Coverage | 0.00 |
Per-Share Data
| Revenue per share | 0.14 |
| Book Value per share | 18.10 |
| Cash per share | 24.50 |
| FCF per share | -4.98 |
| Tangible Book Value per share | 18.10 |
| Dividend per share | 0.00 |
Related companies: ACLX · AKRO · ARWR · CYTK · KRYS · MTSR · NUVL
Explore sector: Healthcare · Biotechnology
More sections of CRSP: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks